- Home
- ABUS vs IMNM Comparison
ABUS vs IMNM Comparison
Compare ABUS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- IMNM
- Stock Information
- Founded
- ABUS N/A
- IMNM 2006
- Country
- ABUS United States
- IMNM United States
- Employees
- ABUS N/A
- IMNM N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- ABUS Health Care
- IMNM Health Care
- Exchange
- ABUS Nasdaq
- IMNM Nasdaq
- Market Cap
- ABUS 697.3M
- IMNM 747.7M
- IPO Year
- ABUS N/A
- IMNM 2020
- Fundamental
- Price
- ABUS $3.21
- IMNM $10.97
- Analyst Decision
- ABUS Strong Buy
- IMNM Strong Buy
- Analyst Count
- ABUS 4
- IMNM 5
- Target Price
- ABUS $5.50
- IMNM $28.60
- AVG Volume (30 Days)
- ABUS 903.4K
- IMNM 911.8K
- Earning Date
- ABUS 11-06-2024
- IMNM 11-13-2024
- Dividend Yield
- ABUS N/A
- IMNM N/A
- EPS Growth
- ABUS N/A
- IMNM N/A
- EPS
- ABUS N/A
- IMNM N/A
- Revenue
- ABUS $6,742,000.00
- IMNM $10,129,000.00
- Revenue This Year
- ABUS N/A
- IMNM N/A
- Revenue Next Year
- ABUS N/A
- IMNM N/A
- P/E Ratio
- ABUS N/A
- IMNM N/A
- Revenue Growth
- ABUS N/A
- IMNM N/A
- 52 Week Low
- ABUS $2.21
- IMNM $8.33
- 52 Week High
- ABUS $4.72
- IMNM $30.96
- Technical
- Relative Strength Index (RSI)
- ABUS 33.77
- IMNM 39.61
- Support Level
- ABUS $3.13
- IMNM $10.76
- Resistance Level
- ABUS $3.61
- IMNM $15.13
- Average True Range (ATR)
- ABUS 0.17
- IMNM 0.98
- MACD
- ABUS -0.03
- IMNM -0.29
- Stochastic Oscillator
- ABUS 12.12
- IMNM 4.81
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.